1. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study). (10th May 2021) Authors: Rummel, Mathias J.; Janssens, Ann; MacDonald, David; Keating, Mary‐Margaret; Zaucha, Jan M.; Davis, Jaclyn; Lasher, Janet; Babanrao Pisal, Chaitali; Izquierdo, Miguel; Friedberg, Jonathan W. Journal: British journal of haematology Issue: Volume 193:Number 6(2021) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results. Issue 8 (27th May 2022) Authors: Lai, Yong‐Rong; Cappellini, Maria Domenica; Aydinok, Yesim; Porter, John; Karakas, Zeynep; Viprakasit, Vip; Siritanaratkul, Noppadol; Kattamis, Antonis; Liu, Rongrong; Izquierdo, Miguel; Lasher, Janet; Govindaraju, Sameera; Taher, Ali Journal: American journal of hematology Issue: Volume 97:Issue 8(2022) Page Start: E281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study. (24th May 2014) Authors: Petersenn, Stephan; Bollerslev, Jens; Arafat, Ayman M.; Schopohl, Jochen; Serri, Omar; Katznelson, Laurence; Lasher, Janet; Hughes, Gareth; Hu, Ke; Shen, George; Reséndiz, Karina Hermosillo; Giannone, Vanessa; Beckers, Albert Journal: Journal of clinical pharmacology Issue: Volume 54:Number 11(2014:Nov.) Page Start: 1308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗